Alto Neuroscience, Inc. (ANRO) Financials

ANRO Assets vs Liabilities
DateAssetsLiabilities
June 30, 2026 254.1 million 34.8 million
March 31, 2026 276.3 million 32.9 million
Dec. 31, 2025 184.7 million 33.5 million
Sept. 30, 2025 147.0 million 35.4 million

ANRO Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
June 30, 2026 -19.8 million 3.6 million
March 31, 2026 -27.6 million 2.8 million
Dec. 31, 2025 -11.5 million 1.9 million
Sept. 30, 2025 -9.9 million 2.2 million

ANRO Net Income

No data available :(

ANRO Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
June 30, 2026 243.7 million 3.3 million -
March 31, 2026 263.8 million 3.6 million 4.9 million
Dec. 31, 2025 176.5 million 18.4 million 3.8 million
Sept. 30, 2025 137.8 million 22.4 million 5.1 million

ANRO Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
June 30, 2026 42.8 million
March 31, 2026 32.9 million
Dec. 31, 2025 31.9 million
Sept. 30, 2025 27.1 million

ANRO Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
June 30, 2026 - 22.1 million 7.0 million -
March 31, 2026 556000 20.3 million 6.8 million -
Dec. 31, 2025 - 12.0 million 5.1 million -
Sept. 30, 2025 - 10.5 million 4.4 million -

ANRO Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
June 30, 2026 - -
March 31, 2026 - 184000
Dec. 31, 2025 - 157000
Sept. 30, 2025 - 164000

ANRO

Price: $21.94

52 week price:
2.12
37.48

Earnings Per Share: -2.32 USD

Exchange: NYQ

Sector: Healthcare

Industry: Biotechnology

Market Capitalization: 825.4 million

Links: